Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-193 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 22, 2019 Category: Research Source Type: funding
The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required)
Funding Opportunity RFA-CA-19-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from approp...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 10, 2019 Category: Research Source Type: funding
The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed)
Funding Opportunity RFA-CA-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 10, 2019 Category: Research Source Type: funding
Notice of Change in Eligible Organizations in PA-18-629 Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)" to Allow Foreign Components in Domestic Applications
Notice NOT-CA-18-059 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 26, 2018 Category: Research Source Type: funding
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Funding Opportunity PA-18-629 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 5, 2018 Category: Research Source Type: funding
Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3 Clinical Trial Optional)
Funding Opportunity PAR-18-248 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2017 Category: Research Source Type: funding
Request for Information (RFI): Information Resources on Lifestyle and Behavioral Factors Contributing to the Effectiveness of Cancer Therapies
Notice NOT-CA-18-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 2, 2017 Category: Research Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R21 Clinical Trial Optional)
Funding Opportunity PA-18-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 2, 2017 Category: Research Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R01 Clinical Trial Optional)
Funding Opportunity PA-18-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evalua...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 2, 2017 Category: Research Source Type: funding
Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)
Funding Opportunity RFA-CA-17-044 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers. The DRSCs are designed to target the following area designated as a scientific priority by ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 20, 2017 Category: Research Source Type: funding
Notice of Correction in Expiration Date for PAR-17-331 "Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)"
Notice NOT-CA-17-075 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 1, 2017 Category: Research Source Type: funding
Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)
Funding Opportunity PAR-17-331 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technol...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2017 Category: Research Source Type: funding
Notice of Correction to PAR-17-128 "Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)"
Notice NOT-CA-17-064 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 19, 2017 Category: Research Source Type: funding
Notice of Change to Key Dates in PAR-17-128 "Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)"
Notice NOT-CA-17-039 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 6, 2017 Category: Research Source Type: funding
Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)
Funding Opportunity ID: 291309 Opportunity Number: PAR-17-128 Opportunity Title: Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: EducationHealthCategory Explanation: CFDA Number(s): 93.39493.395Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal government...
Source: Grants.gov - February 19, 2017 Category: Research Tags: Education Health Source Type: funding
